In this article
Novo Nordisk
will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity treatment in the U.S.
The drug’s cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose. That fuels hopes that pills could help address the longstanding affordability hurdles tied to the weekly injections dominating the weight loss drug market.
The official launch of the oral drug, called the Wegovy pill, comes just two weeks after U.S. regulators cleared the treatment.
